Bezuclastinib and Sunitinib for Gastrointestinal Stromal Tumors

Bezuclastinib and Sunitinib for Gastrointestinal Stromal Tumors
100%75%50%25%0%May 21May 22May 23May 24May 25May 21 • YES 40.1%May 22 • YES 41.2%May 23 • YES 42.1%May 24 • YES 29.4%May 25 • YES 29.9%
ResolvedPositive
Oracle Evidence
ClinicalNewsTrialPositionsReasoningOracle
Resolved Date
11/10/25
Study Completion
9/1/26
Sponsor
Cogent Biosciences, Inc.
Ticker
$COGT
Type
Phase 3
Trial Status
Active, not recruiting
Trial Size
442
NCT
NCT05208047
Trial Description
This Phase 3 trial tests bezuclastinib plus sunitinib for advanced gastrointestinal stromal tumors, measuring time until cancer worsens.